An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo […]
